Retinopathy of Prematurity (ROP)

NewsGuard 100/100 Score

Retinopathy of prematurity (ROP) is a condition of the eye that threatens sight, and is seen typically in children whose body weight is at or below 1250 grams, or who are born before the 31st week of pregnancy is completed.

The risk of developing ROP increases as the gestational age at which the baby is born goes down. The incidence is going up because of the increased survival of very low birth weight babies with modern technology.

This condition is among the major causes of childhood visual impairment. Its effects occur in both eyes, and may last throughout life in the form of poor sight and blindness. However, in the 90% of cases where the deficiency of vision is very mild, normal vision may be regained. The remaining 10% of infants with ROP remain severely visually challenged or are legally blind.

Animation: Retinopathy of Prematurity (ROP)

Stages of ROP

ROP occurs in different stages, namely:

Stage 1: A mild degree of retinal vessel growth, which is often associated with transient visual impairment
Stage 2: Moderately abnormal retinal vessel growth, again often transient, which eventually resolves spontaneously
Stage 3: Severely abnormal retinal growth, in which the blood vessels grow towards the center of the eye rather than along the retinal surface. This is often associated with plus disease, an advanced phase of stage 3, in which the retinal vessels themselves become dilated and tortuous. The threatened outcome with plus disease in stage 3 is retinal detachment. Few infants with stage 3 disease escape with normal vision.
Stage 4: Partial detachment of the retina, due to traction produced by scar tissue on the retinal surface. This in turn is the result of subretinal hemorrhage from the abnormal and fragile vessels.
Stage 5: Complete retinal detachment, which results in serious visual loss or blindness. This is the final stage of the disease.

Complications of ROP

Most infants who have ROP develop either stages 1 or 2, and grow up to have normal vision. However, ROP is still associated with a higher chance of complications in later life such as:

  • Retinal detachment
  • Myopia
  • Squint
  • Amblyopia
  • Glaucoma

For this reason, such patients require lifelong follow up.

Causes of ROP

ROP is due to a failure of the retinal vessels to grow to the edges of the developing retina, because of very preterm delivery.

Retinal development is normally completed within the last trimester of pregnancy.

In babies born before 31 weeks, the retinal vessels have not reached the periphery of the retina, which is therefore deprived of adequate blood supply.

The resulting chemical signals from the retina are presumed to stimulate vascular growth, resulting in the appearance of fragile abnormal new vessels on the retina.

These break and bleed easily and result in the formation of retinal scars, which lead to the occurrence of retinal detachment.

Other factors which contribute to the incidence of ROP include:

  • Anemia
  • Blood transfusions
  • Respiratory distress
  • Poor medical status of the infant
  • Apnea
  • Heart disease
  • High carbon dioxide levels in the blood
  • Infection
  • Hypoxemia and acidosis

Diagnosis and Treatment

Since ROP does not produce any symptoms, regular examination of the eyes of premature infants is the only way to detect it.

The treatment of ROP is limited to techniques which destroy the peripheral relatively avascular parts of the retina, and thus prevent neovascularization of this region.

Laser photocoagulation is used to produce controlled burns, while cryotherapy uses a freezing probe (cryoprobe) to achieve the same aim of irreversible death of the cells in this region.

This is effective in limiting abnormal vascular growth in the retina and preserving macular vision. However, it is achieved at the cost of destroying much of the peripheral visual field.

Scleral buckling and vitrectomy are other approaches which are used at later stages (4 or 5).

In a few cases which conform to strict guidelines, an anti-VEGF molecule called bevacizumab is injected into the eye to arrest and prevent the growth of the abnormal vessels. This molecule may have serious effects on lung and brain development because of its activity against vascular growth, which is why its use is restricted.

If retinal detachment occurs in spite of treatment, it may be left alone if only partial detachment has occurred. However, if it threatens to progress and involve the macula, measures may be taken to reattach the retina, such as laser or cryoretinopexy.

References

Further Reading

Last Updated: Dec 30, 2022

Dr. Liji Thomas

Written by

Dr. Liji Thomas

Dr. Liji Thomas is an OB-GYN, who graduated from the Government Medical College, University of Calicut, Kerala, in 2001. Liji practiced as a full-time consultant in obstetrics/gynecology in a private hospital for a few years following her graduation. She has counseled hundreds of patients facing issues from pregnancy-related problems and infertility, and has been in charge of over 2,000 deliveries, striving always to achieve a normal delivery rather than operative.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Thomas, Liji. (2022, December 30). Retinopathy of Prematurity (ROP). News-Medical. Retrieved on April 18, 2024 from https://www.news-medical.net/health/Retinopathy-of-Prematurity-(ROP).aspx.

  • MLA

    Thomas, Liji. "Retinopathy of Prematurity (ROP)". News-Medical. 18 April 2024. <https://www.news-medical.net/health/Retinopathy-of-Prematurity-(ROP).aspx>.

  • Chicago

    Thomas, Liji. "Retinopathy of Prematurity (ROP)". News-Medical. https://www.news-medical.net/health/Retinopathy-of-Prematurity-(ROP).aspx. (accessed April 18, 2024).

  • Harvard

    Thomas, Liji. 2022. Retinopathy of Prematurity (ROP). News-Medical, viewed 18 April 2024, https://www.news-medical.net/health/Retinopathy-of-Prematurity-(ROP).aspx.

Comments

  1. Peter Aleff Peter Aleff United States says:

    The first cases of ROP were found in 1940 in Boston, and from then on ROP became epidemic in the U.S. but nowhere else. After World War 2, when fluorescent lamps became available in other developed countries, the same parallel between the introduction of those lamps and the start of the ROP epidemic repeated itself. Fluorescent lamps of all types emit a high proportion of their energy at the blue-violet wavelength of 435.8 nanometer, right in the middle of the greatest "blue-light-hazard" measured by Industrial Safety researchers. Adult eyes filter out much of this hazard because they become yellow with age, but the eyes of premature babies are still fully transparent to blue and shorter wavelengths. The damage-weighted retinal irradiance on the retina ofa a preemie reaches in just a few minutes the overdose which the U.S. Industrial Safety Guidelines have established as the danger limit for adult industrial workers during an eight-hour shift. This form of blinding is enhanced by oxygen but not caused by it. Oxygen breathing help had been given to preemies for many decades routinely and generously before 1940 without ever causing any eye damage, and retrospective studies of older blind people confirmed this. The logical solution for ending the ROP epidemic is to replace fluorescent lamps for intensive care nurseries, or else to filter out the blue-violet component of their light. For a detailed documentation of the above, see retinopathyofprematurity.org/...indinglights01.htm and http://retinopathyofprematurity.org/01summary.htm. It is time to end this avoidable iatrogenic eye damage which is a major cause of childhood blindness around the world.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New treatment targeting aging cells could offer lasting relief for diabetic macular edema